Drug firm Pfizer on Monday said it has launched its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. The vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease, it said in a statement.FinanceValue and Valuation Masterclass Batch-1By CA Himanshu JainFinanceValue and Valuation Masterclass - Batch 2By CA Himanshu JainFinanceValue and Valuation Masterclass - Batch 3By CA Himanshu JainArtificial Intelligence AI For Business ProfessionalsBy Vaibhav SisinityFinanceValue and Valuation Masterclass - Batch 4By CA Himanshu JainArtificial IntelligenceAI For Business Professionals Batch 2By Ansh Mehra It enables timely and proactive protection for all adults, including those living with chronic conditions, it added. PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker said. "We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunisation in our country," Pfizer MD Meenakshi Nevatia said. PTI(You can now subscribe to our Economic Times WhatsApp channel) Read More News onpfizerPfizer vaccinepneumococcal diseasePCV20adult immunisationnew vaccine launch India (Catch all the Business News, Breaking News, Budget 2025 Events and Latest News Updates on The Economic Times.) Subscribe to The Economic Times Prime and read the ET ePaper online....moreless (You can now subscribe to our Economic Times WhatsApp channel)Read More News onpfizerPfizer vaccinepneumococcal diseasePCV20adult immunisationnew vaccine launch India(Catch all the Business News, Breaking News, Budget 2025 Events and Latest News Updates on The Economic Times.) Subscribe to The Economic Times Prime and read the ET ePaper online....moreless